Xoma | XOMA - Current Liabilities


Xoma reported $28.3M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Agenus USD 323.49M 36.36M Dec/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Ardelyx USD 88.6M 5.22M Dec/2025
aTyr Pharma USD 113.19M 97.51M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Celldex Therapeutics USD 50.99M 4.53M Dec/2025
Curis USD 14.08M 5.3M Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Incyte USD 1.52B 176.44M Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Prothena USD 40.84M 10.59M Dec/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Xoma USD 28.3M 6.81M Sep/2025